Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | PLAT | P00750 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 3/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4164137 | 0.94 | NOS2 (0.49) | NOS2OPRD1OPRK1PLAUPLAT | |
| SCHEMBL4174478 | 0.92 | PLAU (0.45) | NOS2OPRD1OPRK1PLAUPLAT | |
| SCHEMBL8240266 | 0.87 | NOS2 (0.52) | NOS2OPRD1OPRK1PLAUPLAT | |
| SCHEMBL4159590 | 0.84 | NOS2 (0.58) | NOS2OPRD1OPRK1PLAUPLAT | |
| SCHEMBL13907434 | 0.81 | NOS2 (0.42) | NOS2OPRD1OPRK1PLAUPLAT | |
| SCHEMBL29087294 | 0.80 | OPRK1 (0.47) | OPRD1OPRK1SMN1; SMN2CYP2C19MEN1 | |
| SCHEMBL29087343 | 0.80 | RORC (0.50) | OPRD1OPRK1SMN1; SMN2CYP2C19MEN1 | |
| Hydrochloric Acid SCHEMBL30702535 | 0.79 | RORC (0.49) | OPRD1OPRK1SMN1; SMN2CYP2C19MEN1 | |
| SCHEMBL3024328 | 0.79 | SMN1; SMN2 (0.50) | OPRD1OPRK1SMN1; SMN2CYP2C19MEN1 | |
| Hydrochloric Acid SCHEMBL29087316 | 0.79 | RORC (0.49) | OPRD1OPRK1SMN1; SMN2CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069287-A1 | SUBSTITUTED AZACYCLOALKANES USEFUL FOR TREATING CNS CONDITIONS | PFIZER INC | 2009-03-12 | — | — | US | disclosed |
| US-20090069287-A1 | SUBSTITUTED AZACYCLOALKANES USEFUL FOR TREATING CNS CONDITIONS | PFIZER INC | 2009-03-12 | — | — | US | disclosed |
| US-20090069287-A1 | SUBSTITUTED AZACYCLOALKANES USEFUL FOR TREATING CNS CONDITIONS | PFIZER INC | 2009-03-12 | — | — | US | disclosed |
| EP-1957448-A1 | SUBSTITUTED AZACYCLOALKANES USEFUL FOR TREATING CNS CONDITIONS | Pfizer Products Inc. (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007060526-A1 | SUBSTITUTED AZACYCLOALKANES USEFUL FOR TREATING CNS CONDITIONS | PFIZER PRODUCTS INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007060526-A1 | SUBSTITUTED AZACYCLOALKANES USEFUL FOR TREATING CNS CONDITIONS | PFIZER PRODUCTS INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069287-A1 | SUBSTITUTED AZACYCLOALKANES USEFUL FOR TREATING CNS CONDITIONS | BACE2, BACE1, PMP22 | NOS2 4706/4885OPRD1 1338/4885OPRK1 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.